THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 261 participants.

Also called NCT06559891

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 261 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06559891
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, France, Germany, Greece, Italy (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06559891. Randomized; triple masking; primary purpose treatment. Start 2024-10-03 (actual); primary completion 2027-03-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
Acronym
THRIVE
Condition
Hypertension
Intervention (Device)
TIVUS™ Renal Denervation System
Intervention (Other)
Sham
Lead sponsor
SoniVie Inc. (class: industry)
Collaborator
NAMSA (class: other)
Collaborator
European Cardiovascular Research Center (class: research network)
Collaborator
IQVIA Pty Ltd (class: industry)

Record details

Record id
cardio:ct-nct06559891
Content hash
4f19739b445d821b7af4eb3a1ad8fd88a2167e54c5dcd00802c4aa28df37d3ec